Unicycive Therapeutics Files 8-K for Office Location

Ticker: UNCY · Form: 8-K · Filed: Jun 25, 2024 · CIK: 1766140

Unicycive Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyUnicycive Therapeutics, Inc. (UNCY)
Form Type8-K
Filed DateJun 25, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: administrative, filing-update

Related Tickers: UNCY

TL;DR

UNCY filed an 8-K updating their principal executive office address in Los Altos, CA.

AI Summary

On June 25, 2024, Unicycive Therapeutics, Inc. (UNCY) filed an 8-K report. The filing primarily serves as a notification of their principal executive offices located at 4300 El Camino Real, Suite 210, Los Altos, CA 94022. The company's common stock is traded on the Nasdaq Capital Market under the symbol UNCY.

Why It Matters

This filing updates the company's official address, which is important for regulatory compliance and investor communication.

Risk Assessment

Risk Level: low — The filing is a routine administrative update and does not contain material financial or operational news.

Key Players & Entities

  • Unicycive Therapeutics, Inc. (company) — Registrant
  • 4300 El Camino Real, Suite 210, Los Altos, CA 94022 (location) — Principal Executive Offices
  • UNCY (ticker) — Trading Symbol
  • Nasdaq Capital Market (exchange) — Exchange where common stock is traded

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report the registrant's principal executive offices.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on June 25, 2024.

What is the trading symbol for Unicycive Therapeutics, Inc. common stock?

The trading symbol for Unicycive Therapeutics, Inc. common stock is UNCY.

On which exchange is Unicycive Therapeutics, Inc. common stock traded?

Unicycive Therapeutics, Inc. common stock is traded on the Nasdaq Capital Market.

What is the new address for Unicycive Therapeutics, Inc.'s principal executive offices?

The new address for Unicycive Therapeutics, Inc.'s principal executive offices is 4300 El Camino Real, Suite 210, Los Altos, CA 94022.

Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-06-25 09:15:57

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Unicycive Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40582 81-3638692 (State or other jurisdiction of incorporation or organization) (Commission File Number) IRS Employer Identification No.) 4300 El Camino Real , Suite 210 Los Alto , CA 94022 (Address of principal executive offices) Registrant's telephone number, including area code: ( 650 ) 351-4495 (Former name or former address, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class: Trading Symbol(s) Name of each exchange on which registered: Common Stock UNCY Nasdaq Capital Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD Disclosure. On June 25, 2024, Unicycive Therapeutics, Inc. (the "Company") issued a press release announcing positive results from the Oxylanthanum Carbonate (OLC) UNI-OLC-201 pivotal clinical trial including achievement of both the Primary and Secondary Endpoints. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. In addition, on June 25, 2024, the Company presented its clinical results from the pivotal clinical trial in a corporate presentation. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Form 8-K. The foregoing (including Exhibits 99.1 and 99.2) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 (the "Securities Act"), as amended, or the Exchange Act. Item 9.01. Financial Statements and Exhibits (d) Exhibits. 99.1 Press Release of Unicycive Therapeutics, Inc. dated June 25, 2024. 99.2 Unicycive Therapeutics, Inc. Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 25, 2024 UNICYCIVE THERAPEUTICS, INC. By: /s/ Shalabh Gupta Shalabh Gupta Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.